Biomarin Pharmaceutical (BMRN) EBITDA Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly EBITDA Margin of 14.98% in Q1 2026, up 393.64% on a QoQ basis from 5.1% in Q4 2025, and down 424.0% year-over-year from 4.62% in Q1 2025.
Biomarin Pharmaceutical (BMRN) EBITDA Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed EBITDA Margin across 18 years of filings, most recently posting 14.98% for Q1 2026.
- Quarterly EBITDA Margin fell 424.0% year-over-year to 14.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.0% (down 1075.0% YoY) and the FY2025 annual result came in at 12.71%, down 425.0% from the prior year.
- EBITDA Margin climbed to 14.98% in Q1 2026, from 5.1% in the prior quarter.
- Over five years, EBITDA Margin peaked at 21.6% in Q4 2024 and troughed at 5.1% in Q4 2025.
- A 5-year average of 10.38% and a median of 11.22% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin jumped 1738 bps — and 2025, when it sank 2670 bps.
- Tracing BMRN's EBITDA Margin over 5 years: stood at 2.43% in 2022, then jumped by 273 bps to 4.22% in 2023, then soared by 412 bps to 21.6% in 2024, then slumped by 124 bps to 5.1% in 2025, then jumped by 394 bps to 14.98% in 2026.
- Business Quant data shows BMRN's EBITDA Margin at 14.98% in Q1 2026, 5.1% in Q4 2025, and 2.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 14.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.98% |
| Dec 31, 2025 | -5.10% |
| Sep 30, 2025 | -2.59% |
| Jun 30, 2025 | 21.42% |
| Mar 31, 2025 | 19.22% |
| Dec 31, 2024 | 21.60% |
| Sep 30, 2024 | 11.25% |
| Jun 30, 2024 | 18.96% |
| Mar 31, 2024 | 17.94% |
| Dec 31, 2023 | 4.22% |
| Sep 30, 2023 | 11.22% |
| Jun 30, 2023 | 8.09% |
| Mar 31, 2023 | 7.38% |
| Dec 31, 2022 | -2.43% |
| Sep 30, 2022 | 1.11% |
| Jun 30, 2022 | 8.81% |
| Mar 31, 2022 | 20.31% |
| Dec 31, 2021 | -14.65% |
| Sep 30, 2021 | -6.19% |
| Jun 30, 2021 | 1.39% |